NetworkNewsBreaks – Silo Pharma Inc. (NASDAQ: SI
Post# of 137
(Total Views: 159)
Posted On: 03/03/2023 4:17:21 PM
NetworkNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expands Intellectual Property, Technology Rights for Treating Rare Stress-Related Medical Conditions
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, was recently issued U.S. Patent 11,491,120 for SPC-15 formulation by the U.S. Patent and Trademark Office (“USPTO”). “The patent, titled ‘Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females’, enables SILO to expand its intellectual property and technology rights for treating rare stress-related medical conditions. SPC-15 is a targeted prophylactic ketamine formulation used in a novel protocol to treat and prevent stress-induced affective disorders, including PTSD… SILO collaborates with first-in-class research partners at leading universities to advance research in the medical and psychedelic sectors. The company holds an option to license certain assets currently under development by Columbia University through a commercial evaluation license agreement between both parties. Other drugs in the company pipeline include SPU-16 to treat multiple sclerosis, SPU-21 to treat rheumatoid arthritis, and SPC-14 as a treatment for Alzheimer’s disease,” a recent article reads. “After a comprehensive review by the USPTO, we are pleased with the scope of the granted claims offering further protection for our novel SPC-15 technology and its market potential for anxiety, PTSD and related disorders,” SILO CEO Eric Weisblum is quoted as saying.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, was recently issued U.S. Patent 11,491,120 for SPC-15 formulation by the U.S. Patent and Trademark Office (“USPTO”). “The patent, titled ‘Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females’, enables SILO to expand its intellectual property and technology rights for treating rare stress-related medical conditions. SPC-15 is a targeted prophylactic ketamine formulation used in a novel protocol to treat and prevent stress-induced affective disorders, including PTSD… SILO collaborates with first-in-class research partners at leading universities to advance research in the medical and psychedelic sectors. The company holds an option to license certain assets currently under development by Columbia University through a commercial evaluation license agreement between both parties. Other drugs in the company pipeline include SPU-16 to treat multiple sclerosis, SPU-21 to treat rheumatoid arthritis, and SPC-14 as a treatment for Alzheimer’s disease,” a recent article reads. “After a comprehensive review by the USPTO, we are pleased with the scope of the granted claims offering further protection for our novel SPC-15 technology and its market potential for anxiety, PTSD and related disorders,” SILO CEO Eric Weisblum is quoted as saying.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)SILO Pharma Inc. (SILO) Stock Research Links
Scroll down for more posts ▼